Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acumen Pharmaceuticals, Inc. - Common Stock (NQ:ABOS)

1.070 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.070
Bid (Size) 1.000 (2)
Ask (Size) 1.560 (3)
Prev. Close 1.070
Today's Range 1.070 - 1.070
52wk Range 0.8551 - 3.600
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
A Preview Of Acumen Pharmaceuticals's Earnings
Via Benzinga

Performance

YTD
-42.2%
-42.2%
1 Month
+3.9%
+3.9%
3 Month
-23.0%
-23.0%
6 Month
-54.7%
-54.7%
1 Year
-67.1%
-67.1%

More News

Read More
Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Preview: Acumen Pharmaceuticals's Earnings
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Acumen Pharmaceuticals Earnings Preview
Via Benzinga
Earnings Scheduled For May 13, 2025
Via Benzinga
Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
From Climb Bio, Inc.
Via GlobeNewswire
Tesla To $345? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For March 27, 2025
Via Benzinga
Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual Meeting
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Acumen Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Acumen Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Acumen Pharmaceuticals, Inc. - Common Stock trade on?
Acumen Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Acumen Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Acumen Pharmaceuticals, Inc. - Common Stock is ABOS on the Nasdaq Stock Market
What is the current price of Acumen Pharmaceuticals, Inc. - Common Stock?
The current price of Acumen Pharmaceuticals, Inc. - Common Stock is 1.070
When was Acumen Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Acumen Pharmaceuticals, Inc. - Common Stock was at 06/05/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback